Price fixing, discriminatory pricing, forming cartels... Antitrust violations such as these prevent lawful competition and result in higher prices and less choice for consumers and businesses. A market economy works best when every business has the opportunity to compete freely and fairly.
SRKW has played a prominent role in prosecuting many significant antitrust actions. For example, it led the In re Linerboard Antitrust Litigation (E.D. Pa.) action, which settled for $202 million — the largest ever antitrust settlement in the U.S. Third Circuit Court of Appeals. The Firm served as lead counsel in the In re OSB Antitrust Litigation (E.D. Pa.), where a class of direct purchasers of OSB structural panels used in building homes was certified, and where our complaint was one of the first in the nation to survive challenge under the Supreme Court decision in U.S. v. Twombly. The case settled for $120 million. SRKW is currently lead counsel in the In re Blood Reagents Antitrust Litigation, where the two dominant manufacturers of blood reagents are alleged to have fixed the prices of these tremendously important products.
Other prominent antitrust cases the Firm has led include In re Flat Glass Antitrust Litigation (W.D. Pa.), which settled for $120 million; In re Relafen Antitrust Litigation (D. Mass.), which settled for $75 million to end-payors; Stop and Shop Supermarket Co. v. SmithKline Beecham Corp. (E.D. Pa.), which settled for $100 million; In re Tricor Indirect Purchasers Antitrust Litigation which settled for $62.5 million to the end-payor class and additional monies to opt-out insurers; and In re Mercedes-Benz Antitrust Litigation (D.N.J.), which settled for $17.5 million.
Further, SRKW worked on behalf of businesses overcharged due to an illegal cartel among manufacturers of bulk vitamins and helped recover over $1 billion. We worked for end-payors in the In re Buspirone Antitrust Litigation (S.D.N.Y.), which settled as to all claims by purchasers, state attorneys general, and the Federal Trade Commission, for $670 million. We also worked on behalf of direct purchasers of dynamic random access memory chips, used in computers, in the In re DRAM Antitrust Litigation, MDL Docket 1486 (N.D. Cal.), which settled for more than $325 million.
In addition, our lawyers are currently playing leading roles in a number of antitrust and consumer protection cases against pharmaceutical companies for attempting to prevent competition from low cost generic drugs.
(To read more about our antitrust cases, please click here.)